---
title: "Insilico Medicine plans share buyback of up to HK$ 500 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/303648639.md"
description: "Insilico Medicine announced a share repurchase program of up to HK$500 million on October 30, 2026. The company will use internal financial resources for open-market purchases on the Hong Kong Stock Exchange, excluding proceeds from global offerings. This initiative is authorized under a shareholder mandate granted in June 2026 and remains subject to market conditions and board discretion."
datetime: "2026-10-30T00:16:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/303648639.md)
  - [en](https://longbridge.com/en/news/303648639.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/303648639.md)
generator: "portal-rs"
---

# Insilico Medicine plans share buyback of up to HK$ 500 million

-   Insilico Medicine’s board announced a share repurchase program of up to HK$ 500 million on October 30, 2026. \* Open-market purchases on Hong Kong’s stock exchange will use internal financial resources, excluding global offering proceeds. \* The program falls under the shareholder mandate granted June 2, 2026; implementation remains subject to market conditions and board discretion. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insilico Medicine Cayman Topco published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261030-12388996), on October 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [03696.HK](https://longbridge.com/en/quote/03696.HK.md)

## Related News & Research

- [Insilico Medicine Subsidiary Partners With Luoxin Pharmaceuticals on AI-Powered Drug Discovery](https://longbridge.com/en/news/305433887.md)
- [INSILICO Plans Share Buyback of Up to HKD500M](https://longbridge.com/en/news/303654455.md)
- [Insilico Medicine Reports 40% Response Rate at 130 mg for ISM6331 in Phase 1 Mesothelioma Trial](https://longbridge.com/en/news/303086760.md)
- [Chainfir Capital says AI drug deal headlines mask reliance on uncertain milestone payments](https://longbridge.com/en/news/302495363.md)
- [PRESS DIGEST-New York Times business news - November 20](https://longbridge.com/en/news/306242079.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**